

Table S2. Concomitant treatments during the study.

Pharmacological class or agent	Strontium ranelate 1 g/day (N=558)	Strontium ranelate 2 g/day (N=566)	Placebo (N=559)
All	430 (77%)	424 (75%)	424 (76%)
Propionic acid derivatives (e.g., ibuprofen and naproxen)	136 (24%)	138 (24%)	140 (25%)
Acetic acid derivatives and related substances (e.g. diclofenac and indomethacin)	97 (17%)	100 (18%)	105 (19%)
Anilides (e.g., paracetamol)	221 (40%)	229 (41%)	202 (36%)
Opioids	61 (11%)	63 (11%)	59 (11%)
Topical products for joint and muscular pain	51 (9%)	42 (7%)	56 (10%)
COX-2 inhibitors (e.g., celecoxib and lumiracoxib)	49 (9%)	58 (10%)	33 (6%)
Oxicams (e.g., meloxicam and prxicam)	50 (9%)	51 (9%)	54 (10%)
Corticosteroids (systemic use) for OA	30 (5%)	36 (6%)	26 (5%)
Salicylic acid and derivatives	14 (3%)	13 (2%)	11 (2%)
Glucosamine	3 (0.5%)	7 (1%)	3 (0.5%)
Chondroitin sulphate	2 (0.4%)	0	1 (0.2%)
Glucosamine/chondroitin sulphate combination	0	1 (0.2%)	1 (0.2%)